Gossamer Bio, Inc.GOSSNASDAQ

|||

Switch Symbol:

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 67% recommend buying.

Consensus Rating

Buy

15 analysts·Moderate coverage

67%

Rating Distribution

Strong Buy

00%

Buy

1067%

Hold

427%

Sell

17%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 237% higher.

Bear Case

$9.00

+237%

Consensus

$9.00

+237%

Bull Case

$9.00

+237%

Price Range15 analysts

Low

Consensus

High

$9.00

Current Target

Current Price

$2.67

Upside to Target

$6.33

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.58(7 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+190.92%

EPS—

FY2028

Rev+118.16%

EPS—

FY2029

Rev+71.15%

EPS+228.43%

Earnings Surprises

Beat rate:58%(7/12 quarters)

Avg surprise:+3.7%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 27, 2026Barclays

Gossamer Bio initiated with an Overweight at Barclays

Target:$9.00

+240.9%from $2.64

Sep 10, 2025UBS

Gossamer Bio upgraded to Buy from Neutral at UBS

Target:$9.00

+189.4%from $3.11

Dec 8, 2022H.C. Wainwright

HC Wainwright & Co. Maintains Buy on Gossamer Bio, Lowers Price Target to $5

Target:$5.00

+131.5%from $2.16

Dec 7, 2022Barclays

Barclays Downgrades Gossamer Bio to Equal-Weight, Lowers Price Target to $2

Target:$2.00

-15.3%from $2.36

Dec 7, 2022Raymond James

Raymond James Maintains Outperform on Gossamer Bio, Lowers Price Target to $5

Target:$5.00

+111.9%from $2.36

Dec 6, 2022SMBC Nikko

Gossamer Bio downgraded to Neutral from Outperform at SMBC Nikko

Target:$3.00

+27.1%from $2.36

Apr 26, 2022Barclays

Barclays Maintains Overweight on Gossamer Bio, Lowers Price Target to $12

Target:$12.00

+42.0%from $8.45

Apr 26, 2022Raymond James

Raymond James Maintains Outperform on Gossamer Bio, Lowers Price Target to $10

Target:$10.00

+10.1%from $9.08

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance